Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Open-label extension of a 3-month blinded clinical trial of PTI-125

Award Number: R44AG065152
ORGANIZATION: NATIONAL INSTITUTE ON AGING
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/01/2020
PERIOD OF PERFORMANCE END DATE: 04/30/2021

Group Awards By:

View Award Description

Open-label extension of a 3-month blinded clinical trial of PTI-125 - Project Summary/Abstract PTI-125 is a novel small molecule Alzheimer's disease (AD) therapeutic candidate with a novel target and mechanism of action. PTI-125 binds and reverses an altered conformation of the scaffolding protein filamin A (FLNA) to prevent Aβ42's tight binding to and toxic signaling via the α7-nicotinic acetylcholine receptor (α7nAChR) as well as Aβ42's aberrant activation of toll-like receptor 4 (TLR4). Hence, by restoring FLNA's native shape and blocking these two toxic cascades, PTI-125 reduces both tau hyperphosphorylation and neuroinflammation. Downstream effects include reduced neurofibrillary lesions and amyloid deposits, suggesting disease modification, and improved synaptic plasticity and function of α7nAChR, NMDAR and insulin receptors, suggesting symptomatic improvement. We will pursue a label claim of symptomatic improvement instead of the more difficult claim of disease modification and will therefore conduct clinical studies in mild-to-moderate AD. Under a US IND, the first-in-human clinical trial showed no drug- related adverse effects (AEs) and dose proportional pharmacokinetics (PK). Two Phase 2 multidose studies in mild-to-moderate AD patients of 1-month and 3-month duration, respectively, will measure CSF and plasma/lymphocyte biomarkers and psychiatric/behavioral measures. The already underway 1-month study, a 12-patient open-label study, will also assess PK of twice daily oral dosing of the tablet formulation. The upcoming 3-month blinded study will additionally assess cognition, but not PK. Excellent safety margins have been demonstrated in a 3-month toxicity study in dog and in a 6-month toxicity study in rat. The completion of the 9-month dog toxicity study in May 2019, along with the 6-month rat study, will support clinical trials of any duration. We therefore propose to add a 1-year open-label extension to the 3-month clinical trial both to encourage enrollment and to start our safety database required by FDA. This proposal also includes scale-up and manufacture of PTI-125 tablets to supply this clinical trial, as well as analytical method improvement for PTI-125 Drug Substance to Phase 2/3 standards. The faster acquisition of endpoints for the 3-month blinded clinical trial, along with longer-term dosing for safety and monitoring of disease progression, should greatly enhance interest by potential pharma partners.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2021 ( Subtotal = $0 )
2021	2020	CASSAVA SCIENCES, INC.	7801 N CAPITAL OF TEXAS HWY STE 260	AUSTIN	TX	78731	TRAVIS	USA	Aging Research	000	1	7/13/2021	NEW	$0
														Subtotal = $0

Issue Date FY: 2020 ( Subtotal = $2,499,896 )
2020	2020	CASSAVA SCIENCES, INC.	7801 N CAPITAL OF TEXAS HWY STE 260	AUSTIN	TX	78731	TRAVIS	USA	Aging Research	000	1	4/22/2020	NEW	$2,499,896
2020	2020	CASSAVA SCIENCES, INC.	7801 N CAPITAL OF TEXAS HWY STE 260	AUSTIN	TX	78731	TRAVIS	USA	Aging Research	001	1	5/5/2020	NEW	$0
														Subtotal = $2,499,896

Grand Total All Awards = $2,499,896

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Open-label extension of a 3-month blinded clinical trial of PTI-125

Award Number: R44AG065152

ORGANIZATION: NATIONAL INSTITUTE ON AGING

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/01/2020

PERIOD OF PERFORMANCE END DATE: 04/30/2021

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer